Therapeutics case studies
How we maximise the value of our clients' development approach while reducing costs and timelines
Learn more on how we bring life changing therapies to market.
Providing empirically based guidance and built-to-spec models and solutions across every phase of clinical research and lifecycle management for therapeutic development.
Complex oral semaglutide lactation study
Rapid recruitment and participant-focused support enabled ICON to restore study momentum, reduce risk, and achieve full completion in this rescue study.
Maximising data capture in obesity trials
A global Phase 2/3 obesity trial leveraged a scalable DXA imaging strategy to overcome equipment limitations and eliminate ‘silent attrition,’ ensuring complete visceral fat data capture across a diverse, multi‑site network.
Reducing the time and cost curve
A large pharmaceutical company was conducting a Phase 2 study for adults with obesity. They contracted 42 sites globally, including 6 Accellacare sites in the US to recruit for three cohorts and conduct the study.
Overcoming enrollment challenges in an early phase obesity trial
A large pharma company partnered with ICON to conduct a phase 1 obesity study assessing the safety and tolerability of a new investigational oral amycretin therapy.
Complex phase 1 obesity study
ICON was once again selected as a partner to conduct a phase 1 study in individuals who are overweight or have obesity, evaluating the safety and tolerability of a new subcutaneous GLP-1 and amylin peptide formulation.
Extensive patient access and recruitment strategies
A large pharmaceutical company was conducting a Phase 2 study for adults with a BMI of 18-32. They contracted 60 US sites, including 9 Accellacare sites to recruit for two cohorts and conduct the study.
Proactive patient retention strategy in a GLP-1 RA trial
Explore how ICON successfully supported a sponsor’s cardiovascular outcome trial for a GLP-1 receptor agonist with 9,900+ patients with type 2 diabetes and maintained a retention rate of 97% over 7 years.
High-volume medical imaging to support a MASH clinical trial
A pivotal phase 3 randomised, double-blind study to improve MASH and reduce progression to cirrhosis and/or hepatic decompensation, with high volumes of scans across two imaging modalities.